Precision Medicine and In Vitro Diagnostics

Insights for Precision Medicine and Diagnostics

Expanding into Precision Medicine and Lab Diagnostics was a natural evolution for Purdie Pascoe. Under the leadership of Marianne Fillion, who brings a unique expertise in Precision Medicine and IVD market research, we have endeavoured to become the reference in this area, working closely with large labs, diagnostics companies and pharma/biotech companies developing targeted assets.

Our expertise

CDx and laboratory diagnostic tests are key components of the patient pathways, especially in oncology. With an ever-increasing number of laboratory diagnostic tests, companion diagnostics and targeted therapies being approved over the last few years, the market understanding and skills required to get at the right information to support these assets is vital to a brands success.

Our PM and Diagnostics-focused team has unsurpassed knowledge and understanding of the diagnostics landscape, its stakeholders, strategic challenges and tactical barriers. Uniquely positioned to generate insights from oncologists, haematologists, pathologists, genetic counsellors and other stakeholders, they get involved at every step of the way, from understanding the landscape, advising on the right questions to moderation and data analysis. 

Leading the way with projects such as:

  • Diagnostic journey/ testing algorithm

  • Patient leakage

  • Brand equity

  • Drivers and barriers to test adoption

  • Market access and reimbursement

Featured
Marianne Fillion, VP North America
Marianne Fillion, VP North America

Marianne joined Purdie Pascoe in March 2021, with 20 years’ experience in specialty pharmaceutical market research and strategy.

Most recently, Marianne held the Head of Market Research and subsequently Head of Commercial Analytics and strategy positions at Diaceutics. Before that, she worked for PSL Research and IFOP.

marianne.fillion@purdiepascoe.com

Read More →

“They really dig into the therapy area and the market; other agencies just don’t have the knowledge that they do. That means the first-round hits what we want. You don’t have to hold their hand on projects. They’re also the only agency I have present to my stakeholders – I trust that their responses in presentations will be appropriate. I don’t think other vendors can do this.”

Senior Director, Customer Insights & Business Analytics